Slide 1: Surgical Perfection. For Life.
Stille Surgical Perfection. For Life. September 2025
Slide 2: Disclaimer
DISCLAIMER Certain statements made in this presentation are forward looking statements. Such statements are based on current expectations and are subject to several risks and uncertainties that could cause actual results and performance to differ materially from any expected future results or perfor
Slide 3: Stille meets the clinical need when there is no room for compromise
Stille meets the clinical need when there is no room for compromise. Stille offers market leading products with a focus on the cardiovascular, plastic and microsurgical disciplines. Clinical segments where product quality allows for premium pricing. 3
Slide 4: Specialising in niche surgical instruments & tables
SPECIALISING IN NICHE SURGICAL INSTRUMENTS & TABLES STILLE IN BRIEF BUSINESS UNITS KEY STATISTICS 2024 FY1 Surgical instruments Advanced surgical tables Headquarters Torshälla, Sweden World leading manufacturer of premium surgical instruments and advanced surgical tables Revenues SEK 570m Product po
Slide 5: Stille's global footprint FY 2024
STILLE’S GLOBAL FOOTPRINT FY 2004 North America EMEA RoW EMEA SEK SEK SEK 215m 270m 85m Direct sales Distributor sales Hybrid sales LOCAL OFFICES Sweden HQ, R&D & production MAIN PARTNERS DISTRIBUTORS USA Sales & assembly Germany Switzerland UK Sales & R&D Sales & production Sales & production > 95
Slide 6: Driving growth with clear strategic objectives
DRIVING GROWTH WITH CLEAR STRATEGIC OBJECTIVES 1 2 3 4 PRODUCT LEADERSHIP MARKET EXPANSION OPERATIONAL EXCELLENCE ACQUISITIONS Efficient and scalable Premium offering within Continuous growth and sales manufacturing processes cardiac, cardiovascular, micro, development with strategic Additional grow
Slide 7: Brief introduction to surgical instruments
BRIEF INTRODUCTION TO SURGICAL INSTRUMENTS Stille Ambassador Stille offers a wide range of premium instruments with exceptional quality. Focus is on select attractive clinical niches and segments where Stille offers unique value to its customers and maintains premium pricing power Products are devel
Slide 8: Market opportunities surgical instruments
MARKET OPPORTUNITES SURGICAL INSTRUMENTS MARKET CONSOLIDATION PAVES THE WAY FOR ACQUISITION OPPORTUNITIES The instrument market is fragmented with numerous small and medium-sized companies across various regions, often focusing on niche high-growth surgical segments – Stille is well positioned to ca
Slide 9: Market opportunities surgical tables
MARKET OPPORTUNITES SURGICAL TABLES UNLOCKING NEW BUSINESS OPPORTUNITIES IN HIGH-GROWTH, HIGH-PROFIT SEGMENTS Stille leads the market through in-house development and partnerships with leading C-arm manufacturers. Innovations in technology and software, as well as increased requirements for versatil
Slide 10: Financial KPIs & current performance
FINANCIAL KPIs & CURRENT PERFORMANCE OBJECTIVE ACTUAL 2024 ACTUAL 2020-20243, 4 600 400 ORGANIC SALES GROWTH1 > 10% 11.5% 200 0 2020 2021 2022 2023 2024 30% 25% EBITDA2 > 25% 25.0% 20% 15% 10% 2020 2021 2022 2023 2024 3,0 NET DEBT/EBITDA2 (Long term) <3 -0.6 1,0 -1,0 2020 2021 2022 2023 2024 Note: 1
Slide 11: Sales and profitability development
SALES AND PROFITABILITY DEVELOPMENT SALES DEVELOPMENT FINANCIAL HIGHLIGHTS 600 500 +22.3% CAGR +41.4% CAGR 400 Strong long- term 300 profitable growth in both 200 business units 100 0 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 SEK, m + Fehling1 Gross profit % of 51.9% is EBITDA
Slide 12: Top 10 shareholders
TOP 10 SHAREHOLDERS Name Total Shares1 Votes % Impilo AB 2 056 075 22.9% Linc AB 2 056 075 22.9% Lannebo Kapitalförvaltning 654 522 7.3% SEB Funds 456 434 5.1% Avanza Pension 441 739 4.9% ShapeQ GmbH 418 884 4.7% Ramhill AB 372 209 4.1% Aktia Asset Management 360 353 4.0% Nordnet Pensionsförsäkring
Slide 13: Stille Group in Q2 2025
STILLE GROUP IN Q2 2025 ” Strong order intake but supply-chain constraints and currency headwinds HIGHLIGHTS • Net sales MSEK 124.7 (142.6), -12.6 percent • The gross profit margin 52.1 percent (49.3). • EBITDA* margin 19.6 percent (25.2). • Cash flow from operating activities MSEK 15.1 (19.6) • Sur
Slide 14: Stille – long standing, trusted surgical specialists
STILLE – LONG STANDING, TRUSTED SURGICAL SPECIALISTS A tradition of >180 years of expertise and innovation, trusted by excellence generations of surgeons Unparalleled Unique, premium offering in surgical tables and craftmanship instruments of the highest quality standards Strong global partner & dis
Slide 15: Thank you!
THANK YOU! Surgical perfection, For ie.